In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.
A TWiV threesome explains the observation that humans with inherited T cell CD28 deficiency are susceptible to severe warts driven by human papilloma virus infection, but are otherwise healthy.
The TWiV team reviews the observation that infection with the SARS-CoV-2 Omicron variant causes reduced reproduction and pathogenesis in mice and hamsters.
In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID.
TWiV kicks off 2022 with a review of the virology highlights of 2021, from three virologists, one immunologist, a science writer, and a partridge in a pear tree.
For the final episode of 2021, TWiV reviews an experimental infectious attenuated Lassa fever vaccine based on a codon-deoptimized glycoprotein gene, and SARS-CoV-2 infection of free-ranging white-tailed deer.
In COVID-19 clinical update #95, Daniel Griffin discusses new CDC guidelines for isolation and quarantine, EUA for Molnupiravir, children and COVID, vaccine safety in 5-11 year olds, Omicron outbreaks in Nebraska and Denmark, Baylor’s COVID vaccine, and COVID-OUT for ivermectin.
TWiV explores the impact of the intestinal virome on seroconversion after rotavirus vaccination, and implications of the ability of the SARS-CoV-2 beta variant to infect wild-type laboratory mice.
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
Paul Offit returns to TWiV to discuss new CDC guidance on J&J vaccine, why children should be immunized against COVID-19, and whether or not booster doses are scientifically justified.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.